Merck’s New Glaucoma Drug Zioptan Faces Formidable Market Challenge
This article was originally published in The Pink Sheet Daily
U.S. approval of the prostaglandin analogue adds to Merck’s ophthalmology portfolio, but it remains to be seen whether being preservative free confers tafluprost an advantage in a field that includes generics of the blockbuster Pfizer drug Xalatan.
You may also be interested in...
Tiny Sucampo is betting that its new drug Rescula can make inroads in a heavily generic market because of its clean safety profile and efficacy, but at $99 per 30-day supply WAC, it faces significant headwinds.
Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind.
Like many other big pharma companies, Novartis AG faces an imminent patent cliff, with blood pressure blockbuster Diovan (valsartan), among other products, due to lose patent protection soon.